FDA clears first at-home shot for thyroid eye disease
Roche won FDA approval to market satralizumab (Enspryng) as the first at-home subcutaneous treatment for adults with thyroid eye disease. The decision followed phase 3 SatraGO data showing a 52.9 percent proptosis response and a 60.7 percent diplopia reduction versus placebo in SatraGO-2 among patients with active disease. The drug blocks interleukin-6 receptors.
Where this came from. 2 outlets reported this. We read them, then wrote the sixty words above.